Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter 2017 before the market opens on Monday, March 5, 2018. The Company will hold a conference...

ARQL : 1.84 (+2.79%)
Blog Exposure - ArQule Signed License Agreement with Roivant Sciences to Develop Derazantinib In China

Stock Monitor: Regeneron Pharma Post Earnings Reporting

ARQL : 1.84 (+2.79%)
REGN : 323.86 (+2.55%)
Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China

Roivant Sciences and ArQule, Inc. (NASDAQ: ARQL) today announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR (fibroblast growth factor receptor)...

ARQL : 1.84 (+2.79%)
Galectin Therapeutics (GALT) Jumps: Stock Rises 15.1%

Galectin Therapeutics Inc. (GALT) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.

ARQL : 1.84 (+2.79%)
GALT : 4.32 (+2.37%)
ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma

ArQule, Inc. (Nasdaq: ARQL) today announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib (ARQ 087) in FGFR2 fusion driven second-line intrahepatic...

ARQL : 1.84 (+2.79%)
Cancer Immunotherapy Technology Projected to Create Further Growth

According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at a CAGR of 14.5 percent from the time period of 2016...

CLDX : 2.37 (+0.42%)
ARQL : 1.84 (+2.79%)
RGBP : 0.0439 (-2.01%)
RGBPP : 0.0460 (unch)
ECYT : 3.89 (+4.57%)
CASI : 3.85 (+2.67%)
ArQule, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 9, 2017 / ArQule, Inc. (NASDAQ: ARQL) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 9:00 AM Eastern Time.

ARQL : 1.84 (+2.79%)
ArQule Reports Third Quarter 2017 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2017.

ARQL : 1.84 (+2.79%)
ArQule Announces $9.5 Million Private Placement of Preferred Stock

--Ran Nussbaum, Managing Partner and co-founder of The Pontifax Group, joins ArQule Board

ARQL : 1.84 (+2.79%)
FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome

ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to miransertib (ARQ 092) for the treatment of Proteus...

ARQL : 1.84 (+2.79%)
ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2017 before the market opens on Thursday, November 9, 2017. The Company will hold...

ARQL : 1.84 (+2.79%)
ArQule Announces $15.7 Million Private Placement of Common Stock

ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private placement with certain institutional investors, with leading participation by BVF Partners L.P., pursuant to which the...

ARQL : 1.84 (+2.79%)
ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, M.D., Head of Research and Development and Chief Medical Officer, will present...

ARQL : 1.84 (+2.79%)
ArQule Reports Second Quarter 2017 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2017.

ARQL : 1.84 (+2.79%)
ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies

ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a phase 1a/b trial with its BTK inhibitor, ARQ 531, in patients with B-cell malignancies refractory to...

ARQL : 1.84 (+2.79%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...

ARQL : 1.84 (+2.79%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK , June 26, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach...

ARQL : 1.84 (+2.79%)
ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models was presented at EHA Congress in Madrid,...

ARQL : 1.84 (+2.79%)
ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases

ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a company sponsored phase 1/2 trial with its AKT inhibitor, ARQ 092, in patients with Overgrowth Diseases...

ARQL : 1.84 (+2.79%)
ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that data from a phase 1/2 trial with fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, presented at ASCO demonstrate a meaningful clinical...

ARQL : 1.84 (+2.79%)

Van Meerten Stock Picks

Nvidia - My Favorite S\&P 500 Large Cap Stock
$NVDA Summary96% technical by signals.
NVDA +3.78
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.43%) this morning are up +0.33% on reduced interest rate concerns as the 10-year T-note yield falls below 2.90%. Also, increased M&A activity gave equities a boost after General Mills... Read More

Chart of the Day

Techtarget Inc (TTGT)

TechTarget (TTGT) is the Barchart Chart of the Day.  The Internet content company has a Trend Spotter buy signal, a Weighted Alpha of 107.34+ and gained 88.79% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures saw most contracts steady to fractionally lower on Friday. A private export sale of 115,000 MT was reported by the USDA to Egypt for 17/18 delivery. This morning's USDA Export Sales report indicated that the US sold 1.555 MMT of old crop...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.